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Abstract
Background: COX-2 is an enzyme isoform that catalyses the formation of prostanoids from arachidonic acid. An
increased COX-2 gene expression is believed to participate in carcinogenesis. Recent studies have shown that COX-
2 up-regulation is associated with the development of numerous neoplasms, including skin, colorectal, breast, lung,
stomach, pancreas and liver cancers. COX-2 products stimulate endothelial cell proliferation and their
overexpression has been demonstrated to be involved in the mechanism of decreased resistance to apoptosis.
Suppressed angiogenesis was found in experimental animal studies as a consequence of null mutation of COX-2
gene in mice. Despite the role of COX-2 expression remains a subject of numerous studies, its participation in
carcinogenesis or the thyroid cancer progression remains unclear.
Methods: Twenty three (23) patients with cytological diagnosis of PTC were evaluated. After FNAB examination,
the needle was washed out with a lysis buffer and the obtained material was used for COX-2 expression
estimation. Total RNA was isolated (RNeasy Micro Kit), and RT reactions were performed. b-actin was used as
endogenous control. Relative COX-2 expression was assessed in real-time PCR reactions by an ABI PRISM 7500
Sequence Detection System, using the ΔΔCT method.
Results: COX-2 gene expression was higher in patients with PTC, when compared to specimens from patients with
non-toxic nodular goitre (NTG).
Conclusions: The preliminary results may indicate COX-2 role in thyroid cancer pathogenesis, however the
observed variability in results among particular subjects requires additional clinical data and tumor progression
analysis.
Background
The most common thyroid malignancy is papillary thyr-
oid carcinoma (PTC), accounting for approximately
85-90% of all thyroid cancers. PTC usually grows slowly
and is clinically indolent, although aggressive forms can
also occur. The 10-year survival rate for all PTC patients
is estimated at 80-90% [1].
The introduction of fine-needle aspiration biopsy
(FNAB) has made PTC identification more accurate, but
still the diagnostic tools regarding the differentiation
between thyroid benign and malignant lesions are not
always reliable. The molecular basis of PTC has been
examined and association with variety of molecular
prognostic markers has been described, including RAS,
RET, Trk, MET, and BRAF mutations [2].
Cyclooxygenase-2 (COX-2) is an enzyme isoform
involved in the conversion of arachidonic acid to prosta-
glandin H2, the precursor of various molecules, includ-
ing prostaglandins, prostacyclines and thromboxanes.
COX-2 can be expressed in response to various stimuli,
such as hormones, mitogens, cytokines, inflammatory
mediators and growth factors via protein kinase C and
RAS-mediated signaling [3,4]. The products of COX-2
activity are believed to be involved in carcinogenesis by
promoting angiogenesis, inhibiting apoptosis, increasing
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also modulates vascular endothelial growth factor
(VEGF) production, the factor that promotes angiogen-
esis and decreases immunity toward cancer cells [5-9].
Recent studies have highlighted the relevance of COX-2
in human carcinogenesis. Increased levels of COX-2 have
been reported in numerous tumours, including head and
neck squamous cell cancer, as well as colorectal, breast,
lung, skin, stomach, liver, pancreas, bladder, ovaries and
prostate carcinomas [10-19].
Selective inhibition of COX-2 is a novel therapy under
investigation in both the chemoprevention and treat-
ment of solid tumors [20,21]. Experimental animal data
indicate that COX-2 gene may be associated with carci-
nogenesis of several types of human malignancies.
Whether COX-2 expression is related to the morphol-
ogy of PTC remains unclear. In the present study we
have investigated COX-2 expression in 23 cases of PTC
diagnosed cytologically following FNAB.
Methods
45 thyroid specimens were analyzed, i.e. 23 cases of PTC
and 22 cases of benign thyroid lesions; 6 men and 39
women participated in the study. Patients ranged in age
from 24 to 87 years (median - 48 years in PTC group,
58 years in benign thyroid lesions group). Thyroid aspi-
rates, eligible for the study, were obtained from patients
by fine needle aspiration biopsy (FNAB) in the Clinical
Hospital No. 3, Medical University of Lodz (2007-2010).
Each aspirate was smeared for conventional cytology,
while the remaining part of aspirate was immediately
washed out of the needle. The cells, obtained from the
needle, were used in further investigation. Macroscopi-
cally unchanged thyroid tissue, collected from patients
treated surgically, was used as an internal control.
The procedures, used in the study, were approved by
the Ethical Committee of the Medical University of
Lodz (Poland). All patients were informed and agreed to
participate in this study.
Total RNA was extracted using RNeasy Micro Kit
(Qiagen, Hilden, Germany), based on modified Chomc-
zyński and Sacchi’s method [22]. RNA concentration
was spectrophotometrically assessed by measuring
absorbance at 260 and 280 nm (NanoDrop ND-1000
Spectrophotometer, Thermo Fisher Scientific, USA).
Total RNA was reversely transcribed in a Mastercycler
personal thermocycler (Eppendorf, Hamburg, Germany),
according to manufacturer’sp r o c e d u r e si nat o t a l
volume of 50 μl including oligo d(T)16 (50 μM), Multi-
Scribe Reverse Transcriptase (50 U/μl), 10 × TaqMan
RT Buffer, MgCl2 solution (25 mM), dNTPs mixture
(10 mM), RNAse Inhibitor (20 U/μl) and nuclease-free
water (TaqMan Reverse Trancriptase Reagents, Applied
Biosystems, CA, USA). The reactions were incubated for
10 min in 25°C, 30 min in 48°C, heated for 5 min in
95°C and placed at 4°C.
T h er e l a t i v ee x p r e s s i o no fCOX-2 gene was assessed,
using the ABI PRISM 7500 SDS Software (ABI PRISM
7500 Sequence Detection System, Applied Biosystems),
according to the manufacturer’s protocol. The PCR reac-
tions for COX-2 gene were run with 5 μlo fc D N Ai na
total volume of 50 μl, using TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA, USA) and
predesignated primer/probe set (Assays-on-Demand™
Gene Expression assay, Hs 00153133_m1, Applied Bio-
systems). Amplification reactions were done in triplicate
for each examined sample.
Controls with no template cDNA were used with each
assay. The reference gene was b-actin (Assays-on-
Demand™ Gene Expression assay, Hs 99999903_m1,
Applied Biosystems). Samples of cDNA were quantified
using a fluorescence based real-time detection method
(TaqMan).
Assays-on-Demand Gene Expression product consists
of 20 × mix of unlabelled PCR primers and TaqMan
MGB probe (5 μM) with FAM™(6-carboxy-fluorescein)
at the 5’ end as the reporter dye and a non-fluorescent
quencher (TAMRA, 6-carboxy-tetramethylrhodamine) at
the 3’ end. Cycling conditions were 50°C for 2 min and
95°C for 10 minutes, followed by 50 cycles at 95°C and
60°C for 1 minute. A sample of normal thyroid tissue
served as a calibrator to compare the relative amount of
target in different samples and to adjust for the plate-
to-plate variation in amplification efficiency.
Data and statistical analysis
Relative gene expression - determined by comparing
threshold cycle (CT) for gene of interest (COX-2) with
CTfor the reference gene (b-actin) - was calculated using
the ΔΔCTmethod as described previously [23]. The
characteristics, RQ and ΔCTvalues of patients groups are
shown in Table 1 and Table 2.
Statistical analysis was performed, using a standard
parametric Student’s t test, followed by non-parametric
U Mann-Whitney’s test. P values < 0.05 were considered
to indicate statistical significance.
Results
COX-2 mRNA expression was significantly higher in
PTC when compared to benign thyroid lesions (Stu-
dent’s t-test, P = 0.021). There was no significant rela-
tionship between COX-2 expression and patients age
and sex. The amplification plots of COX-2 and b-actin
are shown in Figure. 1 and 2. The statistical analysis of
COX-2 expression by quantitative Real Time PCR in
PTC and NTG is presented in Figure. 3 and Figure. 4.
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The relation between COX-2 activity and carcinogenesis
is being examined in variety of human neoplasms. Fine
needle aspiration biopsy has become a critical diagnostic
tool in management of thyroid nodules. It has allowed
to decrease the number of cases inquiring surgical treat-
ment from 67% to 44%; also the percentage of operated
carcinomas in those nodules has increased from 14% to
29% [24]. Generally, preoperative discrimination of the
thyroid malignancy, using not only cytopathology but
also molecular markers, would enhance the proper
diagnosis.
In our study, COX-2 expression in both NTG and
PTC were examined. COX-2 expression was significantly
higher in PTC group.
All but one of the previously conducted studies found
overexpression of COX-2 in cases of PTC and follicular
thyroid carcinoma (FTC). In the study of Ito et al. [25],
there were 9 COX-2-negative (18,4%) among 49 of PTC
cases, studied by immunochemistry. They also suggested
significant reduction of COX-2 levels in older patients
(over 54 years old), in patients with large tumors and
with the advanced disease stages, as well as with the
presence of solid, scirrhous or trabecular growth
pattern. An association among and age and worse prog-
nosis has been well-recognized in the medical literature.
Accordingly, Ito et al. [25] found that the COX-2 levels
were significantly reduced in older patients, whereas
Siironen et al. [26] demonstrated the older age group of
patients, having a much worse prognosis and higher
COX-2 levels. However, in our study, we have failed to
establish statistical significance between COX-2 expres-
sion and patients’ age or sex which is similar to results
of Garcia-Gonzales et al [27].
The results of Kajita et al. [28] did not show any sig-
nificant differences in COX-2 expression between nor-
mal thyroid tissue and PTC, because of variation in
mRNA levels. The authors have also performed the in
vitro study, with the TPC-1 thyroid carcinoma cell line
and a compound NS-398 - a COX-2 enzymatic activity
specific inhibitor, showing inhibited growth of tumor
c e l l s .T h e yc o n c l u d e dt h er o l eo fC O X - 2i nt h eg r o w t h
of PTC cell lines.
Cornetta et al. [29] examined a variety of thyroid tis-
sue specimens; COX-2 staining was not observed in
none of the 6 specimens obtained from normal or mul-
tinodular goiter specimens. Analysis of Hashimoto’s
thyroiditis revealed COX-2 expression in the follicular
epithelium and lymphocytic infiltrates, as well as in
cases of FTC and PTC [29].
Table 1 Gender, age, ddCT and RQ values in PTC group
No. Gender Age ddCT RQ
1. M 56 -0.84 1.79
2. M 64 -0.71 1.63
3. F 52 -6.49 89.8
4. F 28 0.95 0.52
5. F 53 -1.62 3.06
6. M 61 -0.62 1.53
7. F 57 -2.46 5.49
8. F 36 -4.07 16.74
9. F 56 -2.76 6.77
10. M 58 -3.12 8.69
11. F 28 1.31 0.4
12. F 24 -1.31 2.48
13. F 67 -1.51 2.84
14. F no data 1.24 2.36
15. F 39 -2.0 4.01
16. F 49 -0.75 1.68
17. F 28 2.86 0.14
18. F 45 -2.75 6.73
19. F 50 -2.11 4.31
20. F 63 -0.86 1.82
21. M 53 -3.98 15.8
22. F 39 -3.44 10.84
23. F 49 -2.22 4.66
Table 2 Gender, age, ddCT and RQ values in NTG group
No. Gender Age ddCT RQ
1. F 27 -0.84 1.79
2. F 87 -0.41 1.32
3. F 65 1.98 0.25
4. F 72 -1.01 2.02
5. F 64 -2.32 4.71
6. F 68 -0.01 1.01
7. F 46 -2.07 4.21
8. F 39 1.55 0.34
9. M 56 -0.63 1.55
10. F 68 -0.98 1.98
11. F 62 2.94 0.13
12. F 48 1.96 0.26
13. F 32 -2.91 7.51
14. M 61 -0.21 1.15
15. F 29 0.74 0.6
16. F 88 -0.68 1.6
17. M 71 -1.53 2.88
18. F 43 -0.46 1.37
19. F 54 0.77 0.24
20. F 50 -1.2 2.3
21. F 79 -1.37 2.59
22. F 71 -0.93 1.9
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sion of COX-2 in thyroiditis, benign and malignant thyr-
oid lesions but not in normal thyroid tissues. They also
observed no correlation between severity of PTC,
regardless of the presence or absence of metastases.
Because of the same intensity of COX-2 staining, found
in thyroiditis, benign and malignant thyroid lesions the
authors concluded that it is unlikely that COX-2 expres-
sion is related to the progression of thyroid disease.
The results of study with Apc
Δ716 knockout mice [31],
s u g g e s t e dt h a tt h ei n d u c t i o no fCOX-2 was a very early
event in colon carcinogenesis. This view has been sup-
ported by Garcia-Gonzales et al. [28] who have sug-
gested that even though COX-2 plays an important role
in progression of all thyroid cancers, in case of PTC it
seems to be more important only in the early stages of
disease.
Conclusions
The usefulness of COX-2 as a marker of thyroid malig-
nancy has been challenged but its potential role in
Figure 1 Representative amplification curves for COX-2 and
b-actin genes in real-time PCR in PTC specimen. 1 a,b,c -
amplification curve for COX-2 gene (mean CT value - 36.694); 2-
amplification curve for b-actin gene (endogenous control) (mean
CT value - 27.071).
Figure 2 Representative amplification curves for COX-2 and
b-actin genes in real-time PCR in macroscopically unchanged
specimen. 1 a,b,c - amplification curve for COX-2 gene (mean
CT value - 31.979); 2 - amplification curve for b-actin gene
(endogenous control) (mean CT value - 27.250).
Figure 3 Box-and-whisker plots representing the COX-2 mRNA
expression by quantitative RT-PCR in PTC and NTG groups.
Results are calculated as ddCT values. Whiskers represent means
± SD (standard deviation) for particular groups. Boxes represent
means ± SEM (standard error of mean). The results were statistically
analyzed, using Student’s t test.
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study, COX-2 expression was found in all studied sam-
ples and the elevated level of COX-2 gene expression
was confirmed in PTC genetic material, collected from
the fine-needle washout fluids. Thus, COX-2 gene may
play a significant role in the pathogenesis of this cancer
type. Furthermore, COX-2 gene overexpression levels
were individually diversified, what may have resulted
from their association with different genetic and clinical
prognostic factors.
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